Market-Moving News for August 18th

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

Benzinga Bulls and Bears: Ross, Moderna, Webull

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.

8-K filing — Amylyx Pharmaceuticals, Inc. (AMLX)

Filed: 2026-08-20 AccNo: 0001193125-26-359418 Size: 411 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

Reported Earlier, Amylyx Pharmaceuticals Prices Upsized $500M Public Offering Of 14,090,000 Common Shares At $35.50 Per Share

Greg Abel Just Made 3 Moves at Berkshire Hathaway That Bet on the Same Trend (And it's Not AI)

Berkshire Hathaway CEO Greg Abel is making significant bets on a housing market recovery through multiple moves: acquiring homebuilder Taylor Morrison for $8.5 billion, increasing investment in Lennar by 30%, and buying shares of D.R. Horton. These moves, combined with existing holdings in Clayton Homes and Berkshire Hathaway Home Services, suggest Abel believes pent-up demand will emerge once mortgage rates decline, despite the currently frozen housing market.

If You'd Invested $1,000 in Home Depot 15 Years Ago, Here's How Much You'd Have Today

A $1,000 investment in Home Depot stock made in August 2011 would be worth approximately $13,900 today, representing a 1,290% total return that significantly outpaced the S&P 500's 757% return over the same period. The company's strong performance was driven by housing market recovery, pandemic-era renovation demand, and aggressive share repurchases that boosted earnings per share fivefold. However, the article suggests such dramatic gains are unlikely to repeat in the next 15 years.